Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-28 00:14 | 2026-01-23 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $68.48 | 131,425 | $8,999,984 | 459,010 | +40.1% |
| 2025-09-30 23:59 | 2025-09-26 | MBX | MBX Biosciences, Inc. | Heron Patrick J | Director, 10% owner | Pharmaceutical Preparations | BUY | $18.00 | 666,666 | $11,999,988 | 5,219,440 | +14.6% |
| 2025-06-18 00:45 | 2025-06-13 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $13.08 | 2,646 | $34,610 | 27,448 | +10.7% |
| 2025-06-06 15:44 | 2025-06-04 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $13.34 | 2,268 | $30,247 | 24,802 | +10.1% |
| 2025-05-23 23:04 | 2025-05-21 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $13.66 | 5,040 | $68,821 | 22,534 | +28.8% |
| 2025-05-19 23:14 | 2025-05-15 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $13.62 | 2,520 | $34,317 | 17,494 | +16.8% |
| 2025-05-15 23:18 | 2025-05-13 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $13.76 | 8,674 | $119,352 | 14,974 | +137.7% |
| 2025-05-13 23:11 | 2025-05-09 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $13.60 | 6,300 | $85,691 | 6,300 | +100.0% |
| 2025-03-19 00:04 | 2025-03-14 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $44.11 | 549 | $24,214 | 168,672 | +0.3% |
| 2025-03-12 23:51 | 2025-03-10 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $43.31 | 2,298 | $99,518 | 168,123 | +1.4% |
| 2025-03-11 00:12 | 2025-03-06 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $43.69 | 1,915 | $83,661 | 165,825 | +1.2% |
| 2025-03-07 01:30 | 2025-03-04 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $45.40 | 1,602 | $72,724 | 163,910 | +1.0% |
| 2024-09-20 23:39 | 2024-09-18 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $37.40 | 115 | $4,301 | 162,308 | +0.1% |
| 2024-09-18 03:09 | 2024-09-16 | MBX | MBX Biosciences, Inc. | Heron Patrick J | Director, 10% owner | Pharmaceutical Preparations | BUY | $16.00 | 625,000 | $10,000,000 | 4,552,774 | +15.9% |
| 2024-09-11 00:04 | 2024-09-06 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $41.58 | 230 | $9,563 | 162,193 | +0.1% |
| 2024-03-07 00:28 | 2024-03-04 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $9.50 | 21,052 | $199,994 | 8,785,284 | +0.2% |
| 2023-11-15 00:35 | 2023-11-09 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $28.30 | 2,910 | $82,353 | 161,963 | +1.8% |
| 2023-09-15 23:56 | 2023-09-13 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $31.02 | 2,625 | $81,425 | 159,053 | +1.7% |
| 2023-09-13 23:39 | 2023-09-11 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | Pharmaceutical Preparations | BUY | $30.44 | 8,437 | $256,791 | 156,428 | +5.7% |
| 2023-09-05 19:51 | 2023-08-31 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director, 10% owner | Pharmaceutical Preparations | BUY | $26.25 | 147,991 | $3,884,764 | 147,991 | +100.0% |
| 2021-07-21 00:54 | 2021-07-20 | IMGO | N/A | Heron Patrick J | Director | Other | BUY | $16.00 | 187,500 | $3,000,000 | 145,918 | +100.0% |
| 2020-06-17 02:13 | 2020-06-16 | PCVX | Vaxcyte, Inc. | Heron Patrick J | Director | Biological Products, (No Diagnostic Substances) | BUY | $16.00 | 250,000 | $4,000,000 | 2,309,554 | +12.1% |
| 2020-03-04 02:54 | 2020-03-03 | PASG | Passage BIO, Inc. | Heron Patrick J | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $18.00 | 550,000 | $9,900,000 | 5,009,219 | +12.3% |
| 2020-02-06 19:27 | 2020-02-04 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director, 10% owner | Pharmaceutical Preparations | BUY | $17.00 | 500,000 | $8,500,000 | 10,542,790 | +5.0% |
| 2019-07-24 23:12 | 2019-07-22 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director, 10% owner | Pharmaceutical Preparations | BUY | $15.00 | 450,000 | $6,750,000 | 3,566,912 | +14.4% |
| 2018-05-31 00:15 | 2018-05-30 | ITRM | Iterum Therapeutics plc | Heron Patrick J | Director, 10% owner | Pharmaceutical Preparations | BUY | $13.00 | 456,099 | $5,929,287 | 341,155 | +100.0% |
| 2015-05-14 23:06 | 2015-05-12 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Heron Patrick J | Director, 10% owner | Pharmaceutical Preparations | BUY | $12.00 | 150,000 | $1,800,000 | 1,887,332 | +8.6% |
| 2015-04-22 21:49 | 2015-04-20 | CDTX | Cidara Therapeutics, Inc. | Heron Patrick J | Director | Biological Products, (No Diagnostic Substances) | BUY | $16.00 | 200,000 | $3,200,000 | 44,355 | +100.0% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.